Filius Bart Buys 150,000 ProQR Therapeutics N.V. Shares

Filius Bart, an executive at ProQR Therapeutics N.V., purchased 150,000 shares of the company at $1.72 each, totaling $257,925, as indicated in the Form 4 filing with the SEC.

Who is Filius Bart and What is His Real Role at ProQR Therapeutics N.V.?

Filius Bart is an executive at ProQR Therapeutics N.V., a publicly traded company focused on developing treatments for various diseases. As an executive, Filius Bart has access to insider information about the company, enabling him to make informed decisions regarding his investments. His real role involves making strategic decisions and managing the company's operations. It is likely that Filius Bart has a deep understanding of the company's financial situation and prospects, leading him to decide to purchase shares.

As an executive, Filius Bart has in-depth knowledge of the company and its activities. He is probably involved in key decisions regarding product development, commercial strategy, and managing the company's resources. His real role provides him with a unique perspective on the opportunities and challenges the company faces, allowing him to make informed investment decisions.

It is important to note that executives of publicly traded companies are obligated to disclose their transactions in company shares within two business days of the transaction, as required by SEC Form 4. This rule aims to promote transparency and enable investors to make informed decisions based on available information.

Transaction Details: 150,000 Shares at $1.72 Each

The transaction involves the purchase of 150,000 ProQR Therapeutics N.V. shares at $1.72 each, totaling $257,925. It is important to note that the per-share price and total transaction value are two distinct figures. The per-share price is the cost of each individual share, while the total transaction value represents the overall amount spent on all purchased shares.

The transaction date was July 21, 2026, and it was disclosed within two business days as required by SEC Form 4. This rule mandates that executives and directors of publicly traded companies disclose their share transactions within a two-day window to promote transparency and allow investors to make informed decisions.

Why Insiders Buy Their Own Shares – Possible Reasons

There are several possible reasons why insiders, such as Filius Bart, may choose to buy shares of their own company. One potential reason is that insiders have confidence in the company's future and believe the shares are undervalued. Insiders may also purchase shares for diversification purposes, aiming to spread their investments and reduce exposure to specific risks.

Insiders may also buy shares as part of a compensation plan or stock program offered by the company. In some cases, insiders might purchase shares for personal reasons, such as tax planning or liquidity needs. It is important to note that insiders may buy shares for reasons not necessarily related to the company's performance.

It is also possible that insiders purchase shares due to their in-depth knowledge of the company and its